报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2024-09-30 | 5.51% | -10.99% | 104.07% | 13/52 | 3.55% | 澳洋健康 | 34.16% | 行业排名> |
2024-06-30 | 2.7% | -7.22% | 143.24% | 18/52 | 2.24% | 澳洋健康 | 30.56% | 行业排名> |
2024-03-31 | 1.11% | -2.63% | -83.33% | 24/52 | 1.22% | 澳洋健康 | 28.14% | 行业排名> |
2023-12-31 | 6.66% | -18.58% | 7.59% | 20/52 | 3.83% | 澳洋健康 | 39.54% | 行业排名> |
2023-09-30 | 6.19% | 2.15% | 112.71% | 22/52 | 6.78% | 澳洋健康 | 61.84% | 行业排名> |
2023-06-30 | 2.91% | 13.23% | 155.26% | 28/52 | 1.93% | 澳洋健康 | 48.34% | 行业排名> |
2023-03-31 | 1.14% | 8.57% | -86.06% | 31/52 | 2.55% | 澳洋健康 | 58.19% | 行业排名> |
2022-12-31 | 8.18% | -28.93% | 34.98% | 24/52 | -0.52% | *ST宜康 | 75.53% | 行业排名> |
2022-09-30 | 6.06% | -32.82% | 135.8% | 30/52 | 11.21% | 博腾股份 | 39.77% | 行业排名> |
2022-06-30 | 2.57% | -43.52% | 144.76% | 31/52 | 5.46% | 睿智医药 | 41.16% | 行业排名> |
2022-03-31 | 1.05% | -63.79% | -90.88% | 28/52 | 3.09% | 澳洋健康 | 51.68% | 行业排名> |
2021-12-31 | 11.51% | 475.5% | 27.61% | 25/52 | -6.4% | 澳洋健康 | 40.93% | 行业排名> |
2021-09-30 | 9.02% | 2% | 98.24% | 22/52 | 2.38% | 金域医学 | 43.58% | 行业排名> |
2021-06-30 | 4.55% | 160.67% | 56.9% | 28/52 | 2.32% | 金域医学 | 35.41% | 行业排名> |
2021-03-31 | 2.9% | 2% | 45% | 16/52 | 1.85% | 阳光诺和 | 26.2% | 行业排名> |
2020-12-31 | 2% | -79.61% | 126.67% | 40/52 | 10.94% | 金域医学 | 13.23% | 行业排名> |
2020-06-30 | -7.5% | -394.12% | -176.45% | 37/52 | 2.51% | 万邦医药 | 52.05% | 行业排名> |
2019-12-31 | 9.81% | 6.28% | 284.71% | 28/52 | 64.11% | 华大基因 | 48.52% | 行业排名> |
2019-06-30 | 2.55% | 10.87% | -72.37% | 19/52 | 5.56% | 华大基因 | 31.24% | 行业排名> |
2018-12-31 | 9.23% | 36.74% | 301.3% | 26/52 | -0.5% | 阳光诺和 | 13.99% | 行业排名> |
2018-06-30 | 2.3% | 2% | -65.93% | 19/52 | 1.7% | 南华生物 | 2848.07% | 行业排名> |
2017-12-31 | 6.75% | -64.77% | -64.77% | 24/52 | 2.03% | 南华生物 | 98.98% | 行业排名> |
2016-12-31 | 19.16% | 2% | 2% | 11/52 | 19.64% | 南华生物 | 82.46% | 行业排名> |